{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:35:38Z","timestamp":1753893338911,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The objective of this case series is to describe the clinical signs and outcome of cyclobenzaprine ingestion in two dogs treated with intralipid emulsion (ILE) and supportive care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case or series summary<\/jats:title><jats:p>Two dogs presented for evaluation of cyclobenzaprine ingestion. A 4-year-old female spayed Rat Terrier (dog 1) presented within 4\u2009h of ingestion of cyclobenzaprine (between 9.7 and 25.9\u2009mg\/kg). The dog experienced abnormal behavior, agitation, tremors, tachycardia, and hypertension. There were no significant clinicopathological abnormalities. The dog was treated with ILE, cyproheptadine, and activated charcoal. All clinical signs resolved after treatment. A 5-month-old female intact mixed-breed dog (dog 2) presented after ingestion of an unknown amount of cyclobenzaprine 2\u20133\u2009h prior to presentation. The dog experienced dull mentation, tremors, loss of gag reflex, tachycardia, and hypertension. There were no significant clinicopathological abnormalities. Orogastric decontamination was performed via gastric lavage, and activated charcoal was given via orogastric tube, followed by ILE. All clinical signs resolved after therapeutic intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This is the first report documenting clinical signs of cyclobenzaprine toxicity in two dogs followed by successful treatment with gastric emptying, ILE, and supportive care.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fvets.2024.1354028","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:18:05Z","timestamp":1707711485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Treatment of cyclobenzaprine ingestion in two dogs with intravenous intralipid therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Kaitlyn","family":"Dreese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adesola","family":"Odunayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa C.","family":"Bucknoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"ref1","first-page":"659","article-title":"Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man","volume":"6","author":"Hucker","year":"1978","journal-title":"Drug Metab Dispos"},{"key":"ref2","first-page":"184","article-title":"Metabolism of cyclobenzaprine in the dog","volume":"6","author":"Hucker","year":"1978","journal-title":"Drug Metab Dispos"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/0736-4679(95)02019-5","article-title":"Five-year multicenter retrospective review of cyclobenzaprine toxicity","volume":"13","author":"Spiller","year":"1995","journal-title":"J Emerg Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6673-1-16","article-title":"Rhabdomyolysis: a manifestation of cyclobenzaprine toxicity","volume":"1","author":"Chabria","year":"2006","journal-title":"J Occup Med Toxicol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000227773","article-title":"Torticollis under cyclobenzaprine","volume":"84","author":"Reuss","year":"2009","journal-title":"Pharmacology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/jpet.121.000998","article-title":"The skeletal muscle relaxer cyclobenzaprine is a potent non-competitive antagonist of histamine H1 receptors","volume":"380","author":"Singh","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ajem.2010.01.014","article-title":"Incidence of tricyclic antidepressant-like complications after cyclobenzaprine overdose","volume":"29","author":"Bebarta","year":"2011","journal-title":"Am J Emerg Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/s0196-0644(86)80999-4","article-title":"Overdose of cyclobenzaprine, the tricyclic muscle relaxant","volume":"15","author":"O'Riordan","year":"1986","journal-title":"Ann Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"281392","DOI":"10.1155\/2013\/281392","article-title":"Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets","volume":"2013","author":"Brioschi","year":"2013","journal-title":"Biomed Res Int"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.20452\/pamw.3877","article-title":"Management of fibromyalgia: practical guides from recent evidence-based guidelines","volume":"127","author":"H\u00e4user","year":"2017","journal-title":"Pol Arch Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/15563658308990071","article-title":"Cyclobenzaprine overdosage","volume":"20","author":"Linden","year":"1983","journal-title":"J Toxicol Clin Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/j.1552-4604.1977.tb01547.x","article-title":"Plasma levels and bioavailability of cyclobenzaprine in human subjects","volume":"17","author":"Hucker","year":"1977","journal-title":"J Clin Pharmacol"},{"year":"2001","key":"ref13"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/0091270002042001007","article-title":"Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency","volume":"42","author":"Winchell","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.177","article-title":"Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome","volume":"90","author":"Mestres","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cvsm.2018.07.006","article-title":"Intravenous lipid emulsions in veterinary clinical toxicology","volume":"48","author":"Gwaltney-Brant","year":"2018","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/jca.21960","article-title":"Treatment of comatose patient from cyclobenzaprine overdose with therapeutic plasma exchange","volume":"37","author":"Buyukgoz","year":"2022","journal-title":"J Clin Apher"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jemermed.2014.10.009","article-title":"Intravenous lipid emulsion in the emergency department: a systematic review of recent literature","volume":"48","author":"Cao","year":"2015","journal-title":"J Emerg Med"},{"year":"2024","key":"ref19"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1740-8261.1984.tb02143.x","article-title":"Gastric emptying in the normal dog","volume":"25","author":"Miyabayashi","year":"1984","journal-title":"Contrast Radiograph. Techniq. Vet. Radiol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1081\/clt-120028749","article-title":"A comparison of the pharmacokinetics of oral and sublingual cyproheptadine","volume":"42","author":"Gunja","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3390\/pharmaceutics15051396","article-title":"Lipid emulsion to treat acute poisonings: mechanisms of action, indications, and controversies","volume":"15","author":"Jaffal","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"756866","DOI":"10.3389\/fmed.2021.756866","article-title":"Mechanisms and efficacy of intravenous lipid emulsion treatment for systemic toxicity from local anesthetics","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s00540-015-2036-6","article-title":"Clinical applications of intravenous lipid emulsion therapy","volume":"29","author":"Muller","year":"2015","journal-title":"J Anesth"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.2460\/javma.239.10.1328","article-title":"Use of intravenous lipid emulsion to treat ivermectin toxicosis in a border collie","volume":"239","author":"Clarke","year":"2011","journal-title":"J Am Vet Med Assoc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5326\/JAAHA-MS-6815","article-title":"Lamotrigine Toxicosis treated with intravenous lipid emulsion therapy in a dog","volume":"56","author":"Hagley","year":"2020","journal-title":"J Am Anim Hosp Assoc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02738-5","article-title":"The effect of intravenous lipid emulsion (ILE) on the pharmacokinetic\/toxicokinetic dispositions of ivermectin and carprofen in rabbits","author":"Akyol","year":"2023","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1354028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:18:08Z","timestamp":1707711488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1354028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":27,"alternative-id":["10.3389\/fvets.2024.1354028"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2024.1354028","relation":{},"ISSN":["2297-1769"],"issn-type":[{"type":"electronic","value":"2297-1769"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"article-number":"1354028"}}